BARINTHUS BIOTHERAPEUT

Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments

07 May 2025 08:00:01 By Nasdaq GlobeNewswire

Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

20 Mar 2025 07:22:19 By Nasdaq GlobeNewswire

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

10 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

25 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

15 Nov 2024 11:02:00 By Nasdaq GlobeNewswire

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

15 Nov 2024 11:01:00 By Nasdaq GlobeNewswire

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

06 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences

31 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer

01 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

24 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results

08 Aug 2024 08:00:01 By Nasdaq GlobeNewswire

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

12 Jun 2024 16:01:00 By Nasdaq GlobeNewswire

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

06 Jun 2024 11:15:00 By Nasdaq GlobeNewswire

Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024

22 May 2024 08:00:00 By Nasdaq GlobeNewswire

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

13 May 2024 08:00:01 By Nasdaq GlobeNewswire

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

01 May 2024 07:00:01 By Nasdaq GlobeNewswire

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

18 Apr 2024 16:10:00 By Nasdaq GlobeNewswire

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

20 Mar 2024 08:15:23 By Nasdaq GlobeNewswire

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

05 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

New partnership aims to advance vaccine against MERS coronavirus

21 Dec 2023 07:31:16 By Nasdaq GlobeNewswire